A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Ruihua Xu, Doctor
- 전화번호: 020-87343468
- 이메일: xurh@syscc.org.cn
연구 장소
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100034
- 아직 모집하지 않음
- Peking University First Hospital
-
연락하다:
- Shikai Wu, Doctor
- 전화번호: 15810037307
- 이메일: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, 중국, 400016
- 아직 모집하지 않음
- The First Affiliated Hospital of Chongqing Medical University
-
연락하다:
- Tao Zhang, Doctor
- 전화번호: 13708311156
- 이메일: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, 중국, 730050
- 아직 모집하지 않음
- Gansu Provincial Tumor Hospital
-
연락하다:
- Zhihu Li, Master
- 전화번호: 18993042850
- 이메일: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, 중국, 528000
- 아직 모집하지 않음
- The First People's Hospital of Foshan
-
연락하다:
- Wei Wang, Doctor
- 전화번호: 18038863618
- 이메일: wangwei@fsyyy.com
-
Guangzhou, Guangdong, 중국, 510060
- 모병
- Sun Yat-sen University Cancer Center
-
연락하다:
- Ruihua Xu, Doctor
- 전화번호: 020-87343468
- 이메일: xurh@syscc.org.cn
-
Guangzhou, Guangdong, 중국, 510000
- 아직 모집하지 않음
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
연락하다:
- Yanhon Den, Doctor
- 전화번호: 13925106525
- 이메일: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, 중국, 530000
- 아직 모집하지 않음
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
연락하다:
- Rong Liang, Doctor
- 전화번호: 18677070811
- 이메일: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, 중국, 563000
- 모병
- The Affiliated Hospital of Zunyi Medical University
-
연락하다:
- Jiwei Wang, Doctor
- 전화번호: 18013964231
- 이메일: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국, 150000
- 아직 모집하지 않음
- Harbin Medical University Cancer Hospital
-
연락하다:
- Tongsen Zheng, Doctor
- 전화번호: 15134569619
- 이메일: zhengtongsen@126.com
-
연락하다:
- Yuxian Bai, Doctor
- 전화번호: 13945095085
- 이메일: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, 중국, 161005
- 아직 모집하지 않음
- Qiqihar First Hospital
-
연락하다:
- Xiyuan Sun, Doctor
- 전화번호: 13945258792
- 이메일: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, 중국, 450000
- 아직 모집하지 않음
- Henan Cancer Hospital
-
연락하다:
- Ying Liu, Doctor
- 전화번호: 13783604602
- 이메일: yaya7207@126.com
-
Zhengzhou, Henan, 중국, 450000
- 아직 모집하지 않음
- The Third People's Hospital of Zhengzhou
-
연락하다:
- HaiCun Wang, Master
- 전화번호: 13803833783
- 이메일: whc1975@126.com
-
Zhengzhou, Henan, 중국, 450000
- 아직 모집하지 않음
- The first affiliated hospital of Zhengzhou university
-
연락하다:
- Yongxu Jia, Doctor
- 전화번호: 15237128281
- 이메일: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, 중국, 434099
- 아직 모집하지 않음
- Jingzhou First People's Hospital
-
연락하다:
- Yan Hu, Master
- 전화번호: 18163137369
- 이메일: helensparkle@163.com
-
Wuhan, Hubei, 중국, 430022
- 아직 모집하지 않음
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
연락하다:
- Hongli Liu, Doctor
- 전화번호: 13995680822
- 이메일: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, 중국, 410013
- 모병
- Hunan Cancer Hospital
-
연락하다:
- Yi He, Doctor
- 전화번호: 18692237222
- 이메일: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210008
- 모병
- Nanjing Drum Tower Hospital
-
연락하다:
- Yudong Qiu, Doctor
- 전화번호: 13951806490
- 이메일: yudongqiu510@163.com
-
Nanjing, Jiangsu, 중국, 210009
- 모병
- Zhongda Hospital Southeast University
-
연락하다:
- CaiLian Wang, Doctor
- 전화번호: 13851756378
- 이메일: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, 중국, 210000
- 아직 모집하지 않음
- Jiangsu Provincial Cancer Hospital
-
연락하다:
- Yuanhua Liu, Doctor
- 전화번호: 13305180356
- 이메일: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330000
- 아직 모집하지 않음
- Jiangxi Provincal People's Hospital
-
연락하다:
- Weirong Yao, Doctor
- 전화번호: 13907002901
- 이메일: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, 중국, 130021
- 아직 모집하지 않음
- Jilin Cancer Hospital
-
연락하다:
- Hongxia Cui, Master
- 전화번호: 13504436090
- 이메일: 2503074283@qq.com
-
Changchun, Jilin, 중국, 130021
- 아직 모집하지 않음
- The first hospital of Jilin University
-
연락하다:
- Tingting Liang, Doctor
- 전화번호: 15804303776
- 이메일: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, 중국, 110000
- 모병
- Liaoning Cancer Hospital & Institute
-
연락하다:
- Jingdong Zhang, Doctor
- 전화번호: 18040007878
- 이메일: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, 중국, 710000
- 아직 모집하지 않음
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
연락하다:
- Aili Suo, Doctor
- 전화번호: 18991232561
- 이메일: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200127
- 모병
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
연락하다:
- XiuYing Xiao, Doctor
- 전화번호: 13564579313
- 이메일: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, 중국, 710000
- 아직 모집하지 않음
- The Second Affiliated Hospital of Air Force Medical University
-
연락하다:
- Haichuan Su, Doctor
- 전화번호: 18629190366
- 이메일: cntdgcp@163.com
-
Xi’an, Shanxi, 중국, 710000
- 아직 모집하지 않음
- The First Affiliated Hospital of Air Force Medical University
-
연락하다:
- Yongzhan Nie, Doctor
- 전화번호: 15091520001
- 이메일: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, 중국, 300202
- 모병
- Tianjin Medical University Cancer Institute & Hospital
-
연락하다:
- Zhanyu Pan, Master
- 전화번호: 18622221256
- 이메일: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, 중국, 300121
- 아직 모집하지 않음
- Tianjin Union Medical Center
-
연락하다:
- Mingqing Zhang, Doctor
- 전화번호: 15122875158
- 이메일: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, 중국, 830054
- 아직 모집하지 않음
- Xinjiang Medical University Affiliated Tumor Hospital
-
연락하다:
- YanLi Qu, Master
- 전화번호: 18160627963
- 이메일: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, 중국, 323000
- 모병
- Lishui Municipal Central Hospital
-
연락하다:
- Yanru Xie, Master
- 전화번호: 13567615770
- 이메일: 43437677@qq.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
활성 비교기: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recommended Phase 2 Dose
기간: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
기간: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
기간: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Half-life
기간: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
기간: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
기간: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
기간: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
기간: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
기간: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
기간: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
기간: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
기간: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
기간: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
공동 작업자 및 조사자
스폰서
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TQB2930-Ib/II-02
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .